Spots Global Cancer Trial Database for Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
Official Title: Evaluation of a Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment in an Underserved Gynecology Population
Study ID: NCT05562778
Interventions
Study Description
Brief Summary: In this study, the investigators aim to compare a mobile health platform, known as a 'chatbot,' that leverages artificial intelligence and natural language processing to scale communication, to 'usual care' that patients would receive. This comparison will enable the investigators to determine if the chatbot system can improve rates of recommendation for genetic testing among patients at elevated risk of harboring a familial cancer syndrome in an all-Medicaid gynecology clinic. Furthermore, the investigators aim to evaluate facilitators of inequity in regard to patient access to and utilization of genetic testing services.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
NYP Brooklyn Methodist Hospital, Brooklyn, New York, United States
NYP Lower Manhattan Hospital, New York, New York, United States
Weill Cornell Medicine, New York, New York, United States
NYP Medical Group Queens, Queens, New York, United States
Contact Details
Name: Melissa K Frey, MD
Affiliation: Weill Medical College of Cornell University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
